Radiopharma start-up raises $175 million

Aktis Oncology, a radiopharmaceutical firm that launched in 2021, has raised $175 million in a series B financing round co-led by RA Capital Management, RTW Investments, and Janus Henderson Investors. Aktis is developing a miniprotein alpha radioconjugate that targets nectin-4 to potentially treat multiple types of tumors. CEO Matthew Roden says in a statement that the funds will allow the firm to test the drug candidate in new patient populations.